IRIDEX (NASDAQ:IRIX) Major Shareholder Buys $13,829.28 in Stock

Posted by Geri Gentry on Oct 10th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin acquired 14,712 shares of IRIDEX stock in a transaction that occurred on Monday, June 16th. The shares were bought at an average price of $0.94 per share, for a total transaction of $13,829.28. Following the transaction, the insider owned 620,630 shares of the company’s stock, valued at $583,392.20. This represents a 2.43% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of NASDAQ IRIX opened at $0.89 on Friday. The company has a market capitalization of $15.64 million, a P/E ratio of -4.45 and a beta of 0.67. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The company has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. As a group, research analysts expect that IRIDEX Corporation will post -0.12 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $3.00.

Read Our Latest Stock Analysis on IRIX

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Weber Capital Management LLC ADV purchased a new position in IRIDEX in the 2nd quarter valued at approximately $206,616. United Capital Financial Advisors LLC purchased a new stake in shares of IRIDEX during the second quarter worth approximately $41,000. Diversify Wealth Management LLC purchased a new stake in shares of IRIDEX in the 1st quarter valued at approximately $35,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the second quarter valued at $30,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of IRIDEX in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 20.10% of the company’s stock.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.